amifostine anhydrous has been researched along with Carcinoma, Epidermoid in 50 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with newly diagnosed squamous cell carcinoma of the head and neck, who were eligible for radiotherapy and who were not receiving concurrent chemotherapy, were randomly assigned to receive either IV amifostine (200 mg/m(2) daily for 3 minutes, 15 to 30 minutes before irradiation) or SC amifostine (500 mg; two sites; 20 to 60 minutes before irradiation)." | 2.76 | Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. ( Alfonsi, M; Aupérin, A; Bardet, E; Boisselier, P; Bourhis, J; Calais, G; Dessard-Diana, B; Feham, NE; Garaud, P; Martin, L; Seng, SH; Tuchais, C, 2011) |
| " There were no reports of Grade >/=3 amifostine-related adverse events." | 2.73 | Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. ( Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007) |
| "Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine." | 2.72 | Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. ( Aekmahachai, M; Chiewvit, S; Chitapanarux, I; Khorprasert, C; Kongthanarat, Y; Lorvidhaya, V; Panichevaluk, A; Phromratanapongse, P; Pusuwan, P; Ratchadara, S; Saengsuda, Y; Shotelersuk, K; Sirilipoche, S; Sukthomya, V; Suntornpong, N; Swangsilpa, T; Tesavibul, C; Veerasarn, V, 2006) |
| "The treatment of head and neck cancer continues to evolve." | 2.71 | Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003) |
| "Xerostomia is the most prevalent late side effect of radiation for head and neck malignancies and is cited by patients as the major cause of decreased quality of life." | 2.71 | Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. ( Chao, KS; Haughey, B; Thorstad, WL, 2003) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| "Xerostomia is one of the most prevalent late side effects of radiation for head and neck malignancies, and patients cite it as the major cause of decreased quality of life." | 2.71 | Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. ( Chao, KS; Haughey, B; Thorstad, WL, 2004) |
| "Adults with head-and-neck cancer who underwent once-daily RT for 5-7 weeks (total dose, 50-70 Gy) received either open-label amifostine (200 mg/m2 i." | 2.71 | Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Sauer, R; Strnad, V; Wasserman, TH, 2005) |
| "Xerostomia was scored subjectively and by whole saliva measurements." | 2.70 | Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. ( Braaksma, M; Levendag, P, 2002) |
| "28 patients with squamous cell carcinomas of the head and neck received adjunctive or primary radiotherapy (5 days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy) in conjunction with carboplatin (70 mg/m2) on days 1-5 and days 21-26." | 2.70 | Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. ( Bennett, CL; Buntzel, J; Glatzel, M; Lane, D; Stinson, T, 2001) |
| "Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis." | 2.69 | Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000) |
| "From a prognosis perspective, head and neck cancers are a heterogeneous group of diseases." | 2.44 | Clinical trial design limitations in head and neck squamous cell carcinomas. ( Awada, A; Bogaerts, J; Lacombe, D; Yun, HJ, 2007) |
| "Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients." | 2.43 | Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006) |
| "Eighteen consecutive patients with squamous cell carcinoma of the head and neck were included in the study." | 1.36 | Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients. ( Henríquez-Hernández, LA; Lara, PC; Lloret, M; Pinar, B; Rodríguez-Gallego, C; Saavedra, MM, 2010) |
| "Chemoradiation induced oral mucositis was delayed and showed significant lower degrees at all 10 Gy increments (p < 0." | 1.30 | Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. ( Bank, P; Beleites, E; Koscielny, S; Trog, D; Wendt, TG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.00) | 18.7374 |
| 1990's | 11 (22.00) | 18.2507 |
| 2000's | 32 (64.00) | 29.6817 |
| 2010's | 4 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, J | 1 |
| Zhu, S | 1 |
| Li, X | 1 |
| Wu, H | 1 |
| Li, Y | 2 |
| Hua, F | 1 |
| Blanchard, P | 1 |
| Bourhis, J | 5 |
| Lacas, B | 1 |
| Le Teuff, G | 1 |
| Michiels, S | 1 |
| Pignon, JP | 1 |
| Rosenthal, DI | 4 |
| Trotti, A | 1 |
| Haddad, R | 2 |
| Sonis, S | 1 |
| Posner, M | 2 |
| Wirth, L | 2 |
| Costello, R | 2 |
| Braschayko, P | 1 |
| Allen, A | 1 |
| Mahadevan, A | 1 |
| Flynn, J | 1 |
| Burke, E | 1 |
| Tishler, RB | 1 |
| Saavedra, MM | 1 |
| Henríquez-Hernández, LA | 1 |
| Lara, PC | 1 |
| Pinar, B | 1 |
| Rodríguez-Gallego, C | 1 |
| Lloret, M | 1 |
| Bardet, E | 2 |
| Martin, L | 2 |
| Calais, G | 2 |
| Alfonsi, M | 1 |
| Feham, NE | 1 |
| Tuchais, C | 2 |
| Boisselier, P | 1 |
| Dessard-Diana, B | 1 |
| Seng, SH | 1 |
| Garaud, P | 1 |
| Aupérin, A | 1 |
| Rhein, B | 1 |
| Feham, N | 1 |
| Alphonsi, M | 1 |
| Rosine, D | 1 |
| Braaksma, M | 1 |
| Levendag, P | 1 |
| Weeks, L | 1 |
| Thorstad, WL | 2 |
| Haughey, B | 2 |
| Chao, KS | 2 |
| Boehme, S | 1 |
| Wilson, DB | 1 |
| Kutter, J | 1 |
| Ozsahin, M | 1 |
| Monnier, P | 1 |
| Stupp, R | 1 |
| Rades, D | 1 |
| Fehlauer, F | 1 |
| Bajrovic, A | 1 |
| Mahlmann, B | 1 |
| Richter, E | 2 |
| Alberti, W | 1 |
| Machtay, M | 1 |
| Chalian, AA | 1 |
| Lustig, R | 1 |
| Hershock, D | 1 |
| Miller, L | 1 |
| Weinstein, GS | 1 |
| Weber, RS | 2 |
| Suntharalingam, M | 1 |
| Jaboin, J | 1 |
| Taylor, R | 1 |
| Wolf, J | 1 |
| Banglore, M | 1 |
| Van Echo, D | 1 |
| Ord, R | 1 |
| Chambers, MS | 1 |
| Eisbruch, A | 1 |
| Cady, J | 1 |
| Blanco, AI | 1 |
| Amrein, PC | 1 |
| Clark, JR | 1 |
| Supko, JG | 1 |
| Fabian, RL | 1 |
| Wang, CC | 1 |
| Colevas, AD | 1 |
| Posner, MR | 1 |
| Deschler, DG | 1 |
| Rocco, JW | 1 |
| Finkelstein, DM | 1 |
| McIntyre, JF | 1 |
| Abitbol, A | 1 |
| Abdel-Wahab, M | 1 |
| Harvey, M | 1 |
| Lewin, A | 1 |
| Troner, M | 1 |
| Hamilton-Nelson, K | 1 |
| Wu, J | 1 |
| Markoe, A | 1 |
| Wasserman, TH | 2 |
| Brizel, DM | 2 |
| Henke, M | 4 |
| Monnier, A | 2 |
| Eschwege, F | 3 |
| Sauer, R | 2 |
| Strnad, V | 3 |
| de Castro, G | 1 |
| Federico, MH | 1 |
| Jellema, AP | 1 |
| Slotman, BJ | 1 |
| Muller, MJ | 1 |
| Leemans, CR | 1 |
| Smeele, LE | 1 |
| Hoekman, K | 1 |
| Aaronson, NK | 1 |
| Langendijk, JA | 1 |
| Veerasarn, V | 1 |
| Phromratanapongse, P | 1 |
| Suntornpong, N | 1 |
| Lorvidhaya, V | 1 |
| Sukthomya, V | 1 |
| Chitapanarux, I | 1 |
| Tesavibul, C | 1 |
| Swangsilpa, T | 1 |
| Khorprasert, C | 1 |
| Shotelersuk, K | 1 |
| Kongthanarat, Y | 1 |
| Panichevaluk, A | 1 |
| Chiewvit, S | 1 |
| Pusuwan, P | 1 |
| Aekmahachai, M | 1 |
| Ratchadara, S | 1 |
| Sirilipoche, S | 1 |
| Saengsuda, Y | 1 |
| Yun, HJ | 1 |
| Bogaerts, J | 1 |
| Awada, A | 1 |
| Lacombe, D | 1 |
| Smith, LH | 1 |
| Law, A | 1 |
| Kennedy, T | 1 |
| Pellitteri, P | 1 |
| Wood, C | 1 |
| Christie, D | 1 |
| Yumen, O | 1 |
| Yuhas, JM | 1 |
| Mitsuhashi, N | 3 |
| Takahashi, I | 3 |
| Takahashi, M | 1 |
| Hayakawa, K | 1 |
| Niibe, H | 3 |
| Wadler, S | 1 |
| Beitler, JJ | 1 |
| Rubin, JS | 1 |
| Haynes, H | 1 |
| McGill, F | 1 |
| Rozenblit, A | 1 |
| Goldberg, G | 1 |
| Cohen, C | 1 |
| Speyer, J | 1 |
| Runowicz, C | 1 |
| Isoda, H | 1 |
| Akagi, K | 1 |
| Murata, T | 1 |
| Aoki, Y | 1 |
| Ikeda, S | 1 |
| Tanaka, Y | 1 |
| Kihara, T | 1 |
| Ikeda, M | 1 |
| Büntzel, J | 4 |
| Küttner, K | 2 |
| Fröhlich, D | 2 |
| Glatzel, M | 3 |
| Johnsson, A | 1 |
| Wennerberg, J | 1 |
| Planting, AS | 1 |
| Catimel, G | 1 |
| de Mulder, PH | 1 |
| de Graeff, A | 1 |
| Höppener, F | 1 |
| Verweij, J | 1 |
| Oster, W | 2 |
| Vermorken, JB | 1 |
| Trog, D | 1 |
| Bank, P | 1 |
| Wendt, TG | 1 |
| Koscielny, S | 1 |
| Beleites, E | 1 |
| Momm, F | 2 |
| Bechtold, C | 2 |
| Fischer, K | 2 |
| Tsekos, A | 2 |
| Vacha, P | 1 |
| Marx, M | 1 |
| Engel, A | 1 |
| Feyerabend, T | 1 |
| Peters, K | 1 |
| Mücke, R | 1 |
| Hamann, D | 1 |
| Ziegler, PG | 1 |
| Fietkau, R | 1 |
| De Crevoisier, R | 1 |
| Abdulkarim, B | 1 |
| Deutsch, E | 1 |
| Lusinchi, A | 1 |
| Luboinski, B | 1 |
| Wibault, P | 1 |
| Gridelli, C | 1 |
| Guida, C | 1 |
| Barletta, E | 1 |
| Gatani, T | 1 |
| Fiore, F | 1 |
| Barzelloni, ML | 1 |
| Rossi, A | 1 |
| de Bellis, M | 1 |
| D'Aniello, R | 1 |
| Scognamiglio, F | 1 |
| Rudat, V | 2 |
| Zhang, J | 1 |
| Russell, L | 1 |
| Bennett, CL | 1 |
| Lane, D | 1 |
| Stinson, T | 1 |
| Antonadou, D | 1 |
| Pepelassi, M | 1 |
| Synodinou, M | 1 |
| Puglisi, M | 1 |
| Throuvalas, N | 1 |
| Weinaug, R | 1 |
| Miyaishi, K | 2 |
| Maehara, Y | 2 |
| Nakajima, N | 2 |
| Suto, H | 2 |
| Saito, Y | 1 |
| Yamakawa, M | 1 |
| Sugiyama, S | 1 |
| Itoh, J | 1 |
| Sakaino, K | 1 |
| Matsuura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Proof of Concept, Efficacy, Safety and Tolerability Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Induced by Radiation Therapy[NCT02399228] | Phase 2 | 13 participants (Actual) | Interventional | 2015-10-04 | Completed | ||
| Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck[NCT00095927] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas[NCT00158691] | Phase 3 | 296 participants | Interventional | 2001-03-31 | Completed | ||
| Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck[NCT00003193] | Phase 1/Phase 2 | 37 participants (Anticipated) | Interventional | 1998-01-31 | Completed | ||
| "Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"[NCT03541772] | Phase 2 | 60 participants (Actual) | Interventional | 2015-01-20 | Completed | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Radiation Therapy Oncology Group (RTOG) is the measure of anatomical changes associated with oral mucositis. Patients scores will be compared to historical data of patient progression.~RTOG Scoring Criteria- Grade 0(none)- No change over baseline Grade 1(mild)- Irritation, may experience slight pain, not requiring analgesic Grade 2(moderate)- Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia Grade 3(severe) -Confluent, fibrinous mucositis, may include severe pain requiring narcotic Grade 4(life-threatening)-Ulceration, hemorrhage, or necrosis" (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| 0.25% EISO Mouth Rinse | 7 |
"Severity of pain in the oral cavity/oropharynx was measured using the numerical rating pain scale (NRPS) at each study visit. The NRPS is an 11-point scale from 0-10:~0 = No pain 10 = The most intense pain imaginable." (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | score on a scale (Mean) |
|---|---|
| 0.25% EISO Mouth Rinse | 3.875 |
"Adverse Events (AEs) will be assessed in accordance the Common Terminology Criteria for Adverse Events (CTCAE). The number of patients experiencing adverse events possibly, or probably related to the study product will be reported.~Possibly related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals.~Probably related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal." (NCT02399228)
Timeframe: [ Time Frame: Up to ten (10) weeks ]
| Intervention | participants (Number) | |
|---|---|---|
| Nausea (Mild) | Vomiting (Mild) | |
| 0.25% EISO Mouth Rinse | 2 | 2 |
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
10 reviews available for amifostine anhydrous and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Ra | 2014 |
[Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Ch | 2015 |
Strategies for managing radiation-induced mucositis in head and neck cancer.
Topics: Acetylcysteine; Amifostine; Carcinoma, Squamous Cell; Glutamine; Head and Neck Neoplasms; Humans; In | 2009 |
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoprotection; Drug Evaluation, Pre | 2002 |
Amifostine-induced fever: case report and review of the literature.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Fever; Head and Neck Neoplasms; Hum | 2004 |
Navigating external beam radiation therapy for head and neck cancer.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Ma | 2005 |
Head and neck squamous cell carcinoma: optimizing the therapeutic index.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2005 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S | 2006 |
Clinical trial design limitations in head and neck squamous cell carcinomas.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Recepto | 2007 |
Toxic epidermal necrolysis.
Topics: Amifostine; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Critical Care; Diagnosis, Diff | 2007 |
32 trials available for amifostine anhydrous and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2009 |
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck | 2011 |
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Topics: Amifostine; Carcinoma, Squamous Cell; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Injec | 2002 |
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotecti | 2002 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2003 |
Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Pil | 2003 |
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous C | 2004 |
Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Hum | 2004 |
A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Parotid Gland; Radiation-Prot | 2004 |
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Chronic Disease; Female; Follow-Up Studies; Head and Ne | 2005 |
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Ne | 2006 |
Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Chi-Square Distribution; Female; Head and Neck Ne | 2006 |
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2007 |
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combine | 1993 |
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
Topics: Adult; Aged; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprote | 1998 |
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dose-Response R | 1999 |
[Experiences with sodium selenite in treatment of acute and late adverse effects of radiochemotherapy of head-neck carcinomas. Cytoprotection Working Group in AK Supportive Measures in Oncology Within the scope of MASCC and DKG].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy | 1999 |
[Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
Topics: Amifostine; Blood Cells; Blood Platelets; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Hemoglo | 1999 |
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, | 1999 |
Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; C | 1999 |
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Eruptions; Fea | 2000 |
Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2001 |
Alteration of radiation-induced hematotoxicity by amifostine.
Topics: Amifostine; Blood Platelets; Carcinoma, Squamous Cell; Granulocytes; Head and Neck Neoplasms; Hemogl | 2001 |
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combi | 2002 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Child; Clinical Trial | 1985 |
8 other studies available for amifostine anhydrous and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Apoptosis; Carcinoma, Squamous Cell; Cells, Cultured; Head and Neck Neoplas | 2010 |
Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Topics: Absorption; Adenocarcinoma; Amifostine; Animals; Carcinoma, Squamous Cell; Female; Liver; Mammary Ne | 1980 |
Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Incidence; Infusion | 1993 |
Change in ascorbate radical production in an irradiated experimental tumor with increased tumor size.
Topics: Amifostine; Animals; Ascorbic Acid; Carcinoma, Squamous Cell; Male; Mice; Mice, Inbred C3H; Muscle, | 1996 |
Amifostine as a protector against cisplatin-induced toxicity in nude mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; DNA Adducts; Female | 1999 |
Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Dose F | 1999 |